Hyderabad: Indian Institute of Technology, Hyderabad (IIT-H) on Friday signed a Memorandum of Understanding (MoU) with PharmCadd, a drug design company in Silico, for the development of shared new drugs.
Last month, PharmCadd established a local company in India and intensively employed competent Indian researchers.
IIT-H and PharmCadd also agreed to promote collaboration by participating together in global research and development projects.
Safe! You have managed to throw your voteogin to see the results “PharmCadd has designed and optimizes the sequence of MRNA to develop the MRNA Covid-19 vaccine and MRNA vaccine candidates recently applied to new drugs that investigate to start clinical studies 1 / 2a studies in Korea.
This experience, we have expanded the vaccine development platform and improved platform technology with the help of IIT resources, “said Taehyung Kwon, Chief Executive Officer, PharmCadd.
Under this MoU, IIT-H will provide Pharmcad with key members to conduct academic research in artificial intelligence, molecular dynamic simulations and quantum calculations for new drug development.
“IIith has dedicated faculties working on many new techniques and drugs.
Global collaboration in the field of developing this drug will definitely strengthen our ability to develop new formulations and make people healthier,” said Prof.
BS Murty, Director, IIT-H ,